by | Apr 17, 2024 | Publications
Clin Chem Lab Med. 2024 Apr 18. doi: 10.1515/cclm-2024-0416. Online ahead of print. ABSTRACT OBJECTIVES: This study evaluates the HYDRASHIFT assay’s effectiveness in mitigating daratumumab interference on serum protein tests during multiple myeloma (MM)...
by | Apr 17, 2024 | Publications
Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05733-9. Online ahead of print. ABSTRACT Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed patients and varying frequency...
by | Apr 17, 2024 | Publications
Clin Exp Med. 2024 Apr 17;24(1):78. doi: 10.1007/s10238-024-01349-5. ABSTRACT Trace elements are essential micronutrients for the human body. Their roles are indispensable, as they are involved in a wide range of vital biological processes. In this study, we aimed to...
by | Apr 17, 2024 | Publications
Cancer Immunol Immunother. 2024 Apr 17;73(6):100. doi: 10.1007/s00262-024-03688-4. ABSTRACT In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T...
by | Apr 17, 2024 | Publications
Cytojournal. 2024 Mar 18;21:13. doi: 10.25259/Cytojournal_64_2023. eCollection 2024. ABSTRACT OBJECTIVE: Multiple myeloma (MM) is a bone marrow cancer that profoundly affects plasma cells involved in the immune response. Myeloma cells alter the average production of...
by | Apr 17, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005. Online ahead of print. ABSTRACT Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM)....